Delving into the Latest Updates on Chung-Pa-Juhn with Synapse

Overview

Basic Info

Drug Type

Herbal medicine

Synonyms

GCSB, Shinbaro

+ [1]

Target

MMPs

Mechanism

MMPs inhibitors(Matrix metalloproteinase inhibitors)

Therapeutic Areas

Skin and Musculoskeletal Diseases

Active Indication

Osteoarthritis

Inactive Indication-

Originator Organization

Green Cross Holdings Corp.

Active Organization

Green Cross Holdings Corp.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

KR (23 Apr 2014),

Osteoarthritis

Regulation-

Login to view timeline

GCSB-5 ("Shinbaro capsule"), is a mixture of 6 oriental herbs that have anti-inflammatory and analgesic effects along with an excellent safety profile. This study is aimed at investigating efficacy of Shinbaro in the treatment of hand osteoarthritis which needs a long term treatment in a placebo controlled, double-blind randomized trial.

Start Date01 Sep 2013

Sponsor / Collaborator

Seoul National University Hospital

[+1]

NCT01604239 / CompletedPhase 4

A 24 Weeks, Multi-centers, Single Arm Phase IV Study to Evaluate the Safety of 'Shinbaro Capsule' Compared With Historical Data of 'Celebrex Capsule' in Patients With Osteoarthritis

This study investigates if Shinbaro capsule has a lower incident of gastrointestinal events than celecoxib in subjects with osteoarthritis.

Start Date01 May 2012

Sponsor / Collaborator

Green Cross Co., Ltd.

NCT01535417 / CompletedPhase 3

A 12 Weeks, Randomized, Double-blind, Multi-centers, Phase III Study to Evaluate the Efficacy and Safety of Shinbaro Capsule Compared With Celebrex Capsule in Patients With Osteoarthritis of Knee

The purpose of this study is to evaluate the efficacy and safety of 'Shinbaro Capsule', a new herbal anti-arthritic agent, in patients with osteoarthritis of the knee.

Start Date01 May 2009

Sponsor / Collaborator

Green Cross Co., Ltd.

100 Clinical Results associated with Chung-Pa-Juhn

Login to view more data

100 Translational Medicine associated with Chung-Pa-Juhn

Login to view more data

100 Patents (Medical) associated with Chung-Pa-Juhn

Login to view more data

17

Literatures (Medical) associated with Chung-Pa-Juhn

01 Feb 2024·Current Rheumatology Reviews

Efficacy of Herbal Medicine in Hand Osteoarthritis: A Narrative Review

Review

Author: Noorabadi, Parisa ; Aghili, Seyedeh Mehrnaz ; Sahebari, Maryam ; Salari, Masoumeh

Objective:Osteoarthritis (OA) is one of the most prevalent joint disorders in the world that has placed an enormous economic and social burden on governments and healthcare sectors in many countries. Hand OA (HOA) is the most common peripheral arthritis, which is less investigated than knee and hip OA. Due to limited approved drug choices and adverse effects of long-term use of current regimens, we aimed to review the existing evidence that were used as oral herbal medicine to treat HOA.Methods:The PubMed database was searched for both observational and interventional studies that have investigated herbal medicine safety and efficacy in HOA, written in English and published between 2010 and 2022.Results:A total of 5 original articles fulfilled the inclusion criteria, and each article assessed a different herbal regimen. Overall, it seems desirable to add specific herbal treatments to the regimen of HOA patients, specifically in case of early stages of HOA.Conclusion:Currently, the need for a low-risk alternative treatment in HOA patients is felt more than ever. There are reliable references relating to the safety of Korean red ginseng, GCSB-5, XLGB, and GS-GCu in these patients, although their efficacy was limited. Additionally, herbs like curcumin and Boswellia serrata have positively affected patients with knee osteoarthritis. However, there is a lack of strong evidence supporting their effectiveness in hand osteoarthritis (HOA). This emphasizes the potential benefits that these herbs may have for HOA patients.

01 Dec 2023·Archives of Rheumatology

GCSB-5 regulates inflammatory arthritis and pain by modulating the mitogen-activated protein kinase signaling pathway in a murine model of rheumatoid arthritis

Article

Author: Bang, Jihye ; Young Park, Soo ; Kim, Sang-Hyon ; Kim, Gyeonghwa ; Kim, Ji-Min ; Jung, Hye Ra

Objectives: This study aimed to determine whether GCSB-5 has anti-inflammatory and antinociceptive effects in mice with collagen-induced arthritis (CIA), an animal model of rheumatoid arthritis (RA), and investigate the influence of GCSB-5 on the mitogen-activated protein kinase (MAPK) pathway.Materials and methods: The experimental animal study was designed to include five groups: CIA mice treated with GCSB-5 (300 mg/kg), GCSB-5 (600 mg/kg), celecoxib (60 mg/kg), or saline for four weeks, and nontreated control mice. The clinical severity of arthritis was scored. Nociceptive thresholds were measured by using a von Frey dynamic plantar analgesimeter. The MAPK pathway was evaluated in mouse synovium. The expression of channels associated with pain signaling was assessed by western blot and immunohistochemical staining.Results: GCSB-5 treatment diminished the severity of clinical arthritis and increased the nociceptive threshold in mice with CIA. Celecoxib, a positive control drug, also showed comparable changes. Clinical arthritis scores were inversely related to mechanical thresholds. GCSB-5 administration decreased the levels of anti-type II collagen antibody and inflammatory cytokines in the sera of mice with CIA. Furthermore, ERK, p38 MAPK, and JNK phosphorylation were downregulated and TRPV1 and ASIC3 expression were decreased in the synovium of GCSB-5-treated mice compared to salinetreated mice. Interleukin-6-induced TRPV1 and ASIC3 upregulation were also inhibited by GCSB-5 in human RA fibroblast-like synoviocytes in vitro.Conclusion: GCSB-5 decreased inflammatory arthritis and pain in a murine model of RA. The results present evidence that GCSB-5 may be beneficial for relieving pain as well as decreasing inflammation in autoimmune arthritis, such as RA.

01 Jan 2023·Frontiers in neurology

Effects of the administration of Shinbaro 2 in a rat lumbar disk herniation model.

Article

Author: Hong, Jin Young ; Lee, Jinho ; Kim, Won Kyung ; Lee, Sang Kook ; Park, Hyen Joo ; Shin, Joon-Shik ; Koh, Wonil ; Ha, In-Hyuk

The current standard for the pharmacological management of lumbar disk herniation (LDH), involving non-steroidal anti-inflammatory drugs, muscle relaxants, and opioid analgesics, often carries a risk of adverse events. The search for alternative therapeutic options remains a vital objective, given the high prevalence of LDH and the critical impact on the quality of life. Shinbaro 2 is a clinically effective herbal acupuncture against inflammation and various musculoskeletal disorders. Therefore, we explored whether Shinbaro 2 exerts protective effects in an LDH rat model. The results showed that Shinbaro 2 suppressed pro-inflammatory cytokines, interleukin-1 beta, tumor necrosis factor-alpha, disk degeneration-related factors, matrix metalloproteinase-1,-3,-9, and ADAMTS-5 in LDH rats. Shinbaro 2 administration reinstated a behavioral activity to a normal level in the windmill test. The results indicated that Shinbaro 2 administration restored spinal cord morphology and functions in the LDH model. Therefore, Shinbaro 2 exerted a protective effect in LDH via actions on inflammatory responses and disk degeneration, indicating that future research is warranted to assess the action mechanisms further and validate its effects.

100 Deals associated with Chung-Pa-Juhn

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	M09AX	-

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Osteoarthritis	KR	Green Cross Holdings Corp.	23 Apr 2014

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01604239 (Pubmed)	Phase 4	Osteoarthritis	761	GCSB-5	ftlsnjtmzc(poejiguqnd) = fwwubvnolh niqdgqpqov (qcvhsculrm )	Positive	02 Aug 2016
NCT01910116 (Pubmed \| Med Lett Drugs Ther) Manual	Phase 2/3	Osteoarthritis	215	GCSB-5	(ktpjlpeenn) = giwfzmgvci ghvqsaefrh (lcbqidcixl ) View more	Positive	01 Aug 2016
				Placebo	(ktpjlpeenn) = ezovreefds ghvqsaefrh (lcbqidcixl ) View more
NCT01910116 (CTgov)	Phase 2/3	Osteoarthritis	220	Shinbaro (Shinbaro)	clpvsdyghx(rqsioxrmlu) = brbrrrwvsq yodwsvjdns (hyrdannizz, oqgfmxmgmw - ujpyeqfxjk) View more	-	17 Dec 2015
				Placebo (Placebo)	clpvsdyghx(rqsioxrmlu) = waqzdbhsod yodwsvjdns (hyrdannizz, uphulgjyqd - jrmrwbtpct) View more
NCT01910116 (EULAR2015)	Phase 2/3	Osteoarthritis	-	GCSB-5 600 mg	(ddjppurnbj) = vviinvpxwq reazlkyuxb (ysgvprvhit, -23.8 to -0.2) View more	Positive	10 Jun 2015
				Placebo	(ddjppurnbj) = pkstonhohs reazlkyuxb (ysgvprvhit, -16.7 to 6.0) View more